Sotagliflozin, in combination with insulin, for treating type 1 diabetes [ID1376]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 8 January 2020
Diabetic retinopathy - ruboxistaurin [ID382]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Macular oedema (diabetic) - pegaptanib sodium [ID452]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Diabetes - buccal insulin [ID311]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC